Onesource Specialty Pharma Limited — Capital/Financing Update 2026

May 4, 2026

onesource

Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
Cyber One, Unit No. 902, Sector 30A,
Plot No - 4 & 6, Vashi,
Navi Mumbai - 400703, India
T: +91 22 2789 2924

Date: May 04, 2026

| BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 544292 | National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: ONESOURCE |
| --- | --- |

Dear Madam/ Sir,

Sub: Press Release:

Please find enclosed herewith Press Release issued by the Company titled:

OneSource Supports Second Generic Semaglutide Approval in Canada
Enables commercialisation for the first two entrants in the world’s second-largest semaglutide market

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited
Trisha A
Digitally signed by Trisha A
Date: 2026.05.04 09:05:33
+9710

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl. as below

OneSource Specialty Pharma Limited
info@onesourcecdmo.com | www.onesourcecdmo.com
CIN: L74140MH2007PLC432497

---

onesource

OneSource Supports Second Generic Semaglutide Approval in Canada

Enables commercialisation for the first two entrants in the world’s second-largest semaglutide market

Bangalore, India, May 04, 2026 – OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), a leading specialty pharmaceutical CDMO, today announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic® (semaglutide injection).

This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in one of the world’s most significant semaglutide markets.

The milestone reflects a closely integrated development and manufacturing model. Orbicular led the product development and technical program for the complex peptide, while OneSource supported the program as the manufacturing partner, providing end-to-end manufacturing capabilities for the Canadian filing. Commercial supply will be supported from OneSource’s US FDA-approved flagship facility in Bengaluru.

The approval follows a recent tentative approval in the United States supported by OneSource, further reinforcing the company’s growing presence in complex peptide-based injectable programs and its ability to support global partners across highly regulated markets.

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited, said: “We are pleased with these back-to-back approvals from two of our global customers in one of the most important semaglutide markets globally. This milestone reflects the strength of our CDMO platform, our compliance standards, technical expertise, and ability to scale complex drug-device-combination programs for highly regulated markets. Our partnership with Orbicular highlights our role in enabling global commercialization through strong, collaborative ecosystems.”

The Canadian approval builds on momentum from India, where OneSource has been supplying a number of brands marketed by multiple partners following product launches in March.

With a continued focus on complex drug-device combinations, biologics, and oral technology, OneSource is strengthening its position as a global CDMO partner, enabling faster, reliable, and high-quality commercialization for partners worldwide.

---

onesource

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

Institutional Investors Anurag Bhagania CFO Tejaswani Fotedar +91 9004331391 Email: investor-relations@onesourcecdmo.com	Corporate Communication Pallavi Panchmatia: +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com Abhilash Mukherjee: +91 89044 28907 Email: abhilash.mukherjee@onesourcecdmo.com Harsh Sheth: +91 9870631557 Email: harsh.sheth@mslgroup.com